Zobrazeno 1 - 10
of 346
pro vyhledávání: '"VERA J. SUMAN"'
Autor:
Roberto A. Leon-Ferre, Kaitlyn R. Whitaker, Vera J. Suman, Tanya Hoskin, Karthik V. Giridhar, Raymond M. Moore, Ahmad Al-Jarrad, Sarah A. McLaughlin, Donald W. Northfelt, Katie N. Hunt, Amy Lynn Conners, Ann Moyer, Jodi M. Carter, Krishna Kalari, Richard Weinshilboum, Liewei Wang, James N. Ingle, Keith L. Knutson, Stephen M. Ansell, Judy C. Boughey, Matthew P. Goetz, Jose C. Villasboas
Publikováno v:
Breast Cancer Research, Vol 26, Iss 1, Pp 1-11 (2024)
Abstract Background Tumor immune infiltration and peripheral blood immune signatures have prognostic and predictive value in breast cancer. Whether distinct peripheral blood immune phenotypes are associated with response to neoadjuvant chemotherapy (
Externí odkaz:
https://doaj.org/article/b975d37e612b41688982be8b1d8df388
Autor:
Roberto A. Leon-Ferre, Jodi M. Carter, David Zahrieh, Jason P. Sinnwell, Roberto Salgado, Vera J. Suman, David W. Hillman, Judy C. Boughey, Krishna R. Kalari, Fergus J. Couch, James N. Ingle, Maschenka Balkenhol, Francesco Ciompi, Jeroen van der Laak, Matthew P. Goetz
Publikováno v:
npj Breast Cancer, Vol 10, Iss 1, Pp 1-10 (2024)
Abstract Operable triple-negative breast cancer (TNBC) has a higher risk of recurrence and death compared to other subtypes. Tumor size and nodal status are the primary clinical factors used to guide systemic treatment, while biomarkers of proliferat
Externí odkaz:
https://doaj.org/article/76fed00f45b74d1e9623e4f305759050
Autor:
Tina J. Hieken, Garth D. Nelson, Thomas J. Flotte, Eric P. Grewal, Jun Chen, Robert R. McWilliams, Lisa A. Kottschade, Lu Yang, Evidio Domingo-Musibay, Roxana S. Dronca, Yiyi Yan, Svetomir N. Markovic, Anastasios Dimou, Heather N. Montane, Courtney L. Erskine, Mara A. Piltin, Daniel L. Price, Samir S. Khariwala, Jane Hui, Carrie A. Strand, Susan M. Harrington, Vera J. Suman, Haidong Dong, Matthew S. Block
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-12 (2024)
Abstract Both targeted therapies and immunotherapies provide benefit in resected Stage III melanoma. We hypothesized that the combination of targeted and immunotherapy given prior to therapeutic lymph node dissection (TLND) would be tolerable and dri
Externí odkaz:
https://doaj.org/article/6734662876464a8cb916380502e32069
Autor:
Xiaojia Tang, Kevin J. Thompson, Krishna R. Kalari, Jason P. Sinnwell, Vera J. Suman, Peter T. Vedell, Sarah A. McLaughlin, Donald W. Northfelt, Alvaro Moreno Aspitia, Richard J. Gray, Jodi M. Carter, Richard Weinshilboum, Liewei Wang, Judy C. Boughey, Matthew P. Goetz
Publikováno v:
Breast Cancer Research, Vol 25, Iss 1, Pp 1-18 (2023)
Abstract Background Triple-negative breast cancer (TNBC) is the most aggressive breast cancer subtype. Patients with TNBC are primarily treated with neoadjuvant chemotherapy (NAC). The response to NAC is prognostic, with reductions in overall surviva
Externí odkaz:
https://doaj.org/article/3af3f74d177a4754a631cf8c8eef5d57
Autor:
Kirsten G. M. Aspros, Jodi M. Carter, Tanya L. Hoskin, Vera J. Suman, Malayannan Subramaniam, Michael J. Emch, Zhenqing Ye, Zhifu Sun, Jason P. Sinnwell, Kevin J. Thompson, Xiaojia Tang, Esther P. B. Rodman, Xiyin Wang, Adam W. Nelson, Igor Chernukhin, Feda H. Hamdan, Elizabeth S. Bruinsma, Jason S. Carroll, Martin E. Fernandez-Zapico, Steven A. Johnsen, Krishna R. Kalari, Haojie Huang, Roberto A. Leon-Ferre, Fergus J. Couch, James N. Ingle, Matthew P. Goetz, John R. Hawse
Publikováno v:
npj Breast Cancer, Vol 8, Iss 1, Pp 1-15 (2022)
Abstract Triple Negative Breast Cancer (TNBC) accounts for 15–20% of all breast cancer cases, yet is responsible for a disproportionately high percentage of breast cancer mortalities. Thus, there is an urgent need to identify novel biomarkers and t
Externí odkaz:
https://doaj.org/article/cb14a3f8cc2f47efa372c800d589e31a
Autor:
Swaathi Jayaraman, Xiaonan Hou, Mary J. Kuffel, Vera J. Suman, Tanya L. Hoskin, Kathryn E. Reinicke, David G. Monroe, Krishna R. Kalari, Xiaojia Tang, Megan A. Zeldenrust, Jingfei Cheng, Elizabeth S. Bruinsma, Sarah A. Buhrow, Renee M. McGovern, Stephanie L. Safgren, Chad A. Walden, Jodi M. Carter, Joel M. Reid, James N. Ingle, Matthew M. Ames, John R. Hawse, Matthew P. Goetz
Publikováno v:
Breast Cancer Research, Vol 22, Iss 1, Pp 1-12 (2020)
Abstract Background The tamoxifen metabolite, Z-endoxifen, demonstrated promising antitumor activity in endocrine-resistant estrogen receptor-positive (ER+) breast cancer. We compared the antitumor activity of Z-endoxifen with tamoxifen and letrozole
Externí odkaz:
https://doaj.org/article/1f0ba8cf46c9435685e14beccf269d8f
Autor:
Bhavika K. Patel, Jennifer L. Ridgeway, Karthik Ghosh, Deborah J. Rhodes, Bijan Borah, Sarah Jenkins, Vera J. Suman, Aaron Norman, Matt Jewett, Davinder Singh, Celine M. Vachon, Carmen Radecki Breitkopf
Publikováno v:
Trials, Vol 20, Iss 1, Pp 1-11 (2019)
Abstract Background Breast cancer is the most common cancer and the leading cause of cancer mortality among Latinas. As more is learned about the association between mammographic breast density (MBD) and breast cancer risk, a number of U.S. states ad
Externí odkaz:
https://doaj.org/article/87091b1ca24a4eda95f5f57bb7939a9e
Autor:
Jia Yu, Bo Qin, Ann M. Moyer, Jason P. Sinnwell, Kevin J. Thompson, John A. Copland, Laura A. Marlow, James L. Miller, Ping Yin, Bowen Gao, Katherine Minter-Dykhouse, Xiaojia Tang, Sarah A. McLaughlin, Alvaro Moreno-Aspitia, Anthony Schweitzer, Yan Lu, Jason Hubbard, Donald W. Northfelt, Richard J. Gray, Katie Hunt, Amy L. Conners, Vera J. Suman, Krishna R. Kalari, James N. Ingle, Zhenkun Lou, Daniel W. Visscher, Richard Weinshilboum, Judy C. Boughey, Matthew P. Goetz, Liewei Wang
Publikováno v:
Breast Cancer Research, Vol 19, Iss 1, Pp 1-13 (2017)
Abstract Background Patient-derived xenografts (PDXs) are increasingly used in cancer research as a tool to inform cancer biology and drug response. Most available breast cancer PDXs have been generated in the metastatic setting. However, in the sett
Externí odkaz:
https://doaj.org/article/ff08d7b126a94ac2ae38cf69dca307e2
Autor:
Jia Yu, Bo Qin, Ann M. Moyer, Jason P. Sinnwell, Kevin J. Thompson, John A. Copland, Laura A. Marlow, James L. Miller, Ping Yin, Bowen Gao, Katherine Minter-Dykhouse, Xiaojia Tang, Sarah A. McLaughlin, Alvaro Moreno-Aspitia, Anthony Schweitzer, Yan Lu, Jason Hubbard, Donald W. Northfelt, Richard J. Gray, Katie Hunt, Amy L. Conners, Vera J. Suman, Krishna R. Kalari, James N. Ingle, Zhenkun Lou, Daniel W. Visscher, Richard Weinshilboum, Judy C. Boughey, Matthew P. Goetz, Liewei Wang
Publikováno v:
Breast Cancer Research, Vol 23, Iss 1, Pp 1-2 (2021)
An amendment to this paper has been published and can be accessed via the original article.
Externí odkaz:
https://doaj.org/article/522cd7669360436690f876e3a87eb7fe
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 11 (2019)
Prior to the advent of the monoclonal antibody trastuzumab, human epidermal growth-factor receptor 2 (HER2)-positive (HER2+) breast cancer (BC) was associated with an aggressive clinical course and poor survival outcomes. In the era of effective HER2
Externí odkaz:
https://doaj.org/article/6b630d255c0643b2a1bf14c82eac9314